Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Chidamide + duvelisib in relapsed/refractory peripheral T-cell lymphoma
ChiCTR2300075965Phase 2Not yet recruiting
- Sponsor
- First Affiliated Hospital of Xiamen University
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of tucidinostat and duvelisib in peripheral T-cell lymphoma (PTCL) and natural killer/T-cell lymphoma (NKTL), sponsored by First Affiliated Hospital of Xiamen University. Primary endpoints: overall response rate and complete response rate. Planned start Sep 2023; status: not yet recruiting.
02
Drugs
tucidinostatduvelisib
03
Conditions
peripheral T-cell lymphoma (PTCL)natural killer/T-cell lymphoma (NKTL)
Beyond the preview
Go deeper on ChiCTR2300075965.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2300075965.